Recently, Beuselinck et al. identified four molecular ccRCC subgroups correlating with VEGFRi (sunitinib) treatment: (1) ccrcc1 (“c-myc-up”) and ccrcc4 (“c-myc-up and immune-up”) with shorter PFS, OS and poorer response to sunitinib, (2) ccrcc2 (“classical”) and ccrcc3 (“normal-like”) with longer OS and better sunitinib response (p < 0.0001). Here, MYC is linked to nonpapillary renal cell carcinoma.